Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit?

A growing body of evidence suggests that sodium-glucose cotransporter 2 (SGLT2) inhibitors appear to be a powerful option to improve the cardiovascular (CV) prognosis in high CV-risk patients with type 2 diabe...

Source: Cardiovascular Diabetology - October 12, 2017 Category: Cardiology Authors: Atsushi Tanaka and Koichi Node Tags: Commentary Source Type: research